Pre-Conference Workshops

Workshop A: Assessing the Current Status of Cell Engagers
Tuesday August 18, 2020


Following the first approval of blinatumomab in 2014, therapeutics designed to utilize immune cell engagement have continued to gather favor with the pharmaceutical industry. As our understanding of immune cell biology and immunotherapy has expanded, so to have the potential to improve therapeutic options. This workshop will review of the core mechanisms of cell engagement (T cell Engagers, NK cell engagers, CAR-T cells, etc.) as well as address some of the common challenges associated with these approaches e.g. on-target offtumor toxicity and Cytokine Release Syndrome (CRS).

Attend this session and learn more about how to maximize the
therapeutic index of cell engagers 

  • What does the target landscape show are the “lowest hanging fruit” – liquid or solid tumors?
  • Current strategies for selection of lead candidates
  • Review preclinical assays used to evaluate cell engagers in vitro and in vivo
  • Lessons learned from early generation T cell engagers in reduction of CRS and other tox issues
  • Emerging technologies to maximize efficacy

Workshop Leader:


Joshua Apgar, Applied Biomath

Josh Apgar
Co-Founder and CSO
Applied Biomath

Antari Khot

Antari Khot
Senior Scientist

Patricia Giblin

Patricia Giblin
VP of Biology

Workshop B: Discussing the Future of Cell Engagers


Redirection of immune cells to eliminate tumor cells holds great promise and new approaches to target T, NK, macrophage and gamma delta cells are exploding. As approaches diversify it becomes more and more challenging to understand the difference in biologies and ensuing complexity in target selection, construct design and preclinical modelling. This workshop will review both the published literature and internal case study experiences to help bring to life the different options for developing next generation cell engagers.

Attend this session to boost your knowledge of:

• Design/protein engineering considerations
• Development of next generation molecules
• Mechanisms of action that can be utilized
• Tumor models with greater predictive power
• Routes to improving clinical efficacy

Workshop Leaders:


Cris Kamperschroer
Malgorzata Nocula-Lugowska a

Cris Kamperschroer
Senior Principal Scientist

Malgorzata Nocula-Lugowska
Senior Principal Scientist